World In Vitro Diagnostics Market Set To Exceed $44 Billion by 2010

New York, April 30, 2006 — Advances in human genomics, bioinformatics, miniaturization, and microelectonics—often blended with IT and computer technology—have led to a rapid growth spurt in the market for in vitro diagnostic tests, with worldwide sales expected to surpass $44.5 billion by 2010, according to a study released today from Kalorama Information.

The new study, The Worldwide Market for In Vitro Diagnostic Tests, predicts that emerging markets, such as South America and Southeast Asia, where rising standards of living have sparked growing demands for quality medical care, will experience 10-20% annual growth. Japan, EU, and the U.S markets, currently making up 85% of the market, will begin to lose market share, with their portion of the market decreasing to 80% by 2010.

Routine test segments—chemistry/immunoassay workstations, hematology, and routine microbiology—currently make up about 70% of the market test wise. But intensive price pressure and automation continuously erode the market value of these segments and more expensive nucleic acid, pharmacogenomic tests and immunoassays for cancer, cardiovascular diseases, and infectious diseases will begin to overshadow these mature industries by 2010. However, these emerging futuristic advances in the market are not immune to regulatory and healthcare system resistance.

“As we’ve seen with avian flu, West Nile, and SARS, the need for companies to be able to react quickly with IVDs targeted at global health problems is intense,” notes Shara Rosen, the report’s author. “Yet, as is often the case, current and emerging technologies are far ahead of most healthcare regulations and reimbursement plans, making many of these newer approaches to patient management inaccessible and/or unaffordable in many areas of the world.”

Spanning more than 1,000 pages, this bestselling report, now in its 5th Edition, has become an industry standard for tracking the most important IVD industry developments, including the movement toward POC and decentralization in lab medicine; miniaturization, and molecularization of devices; non-invasive sampling; and expanded data on PGx and SNP testing. The Worldwide Market for In Vitro Diagnostic Tests can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1187538.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For information, contact Tom Ehart: 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.